1. Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jörneskog G, Wallin G: Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005. Eur J Endocrinol/Eur Fed Endocr Soc. 2008, 158: 823-827.
2. Conference Proceeding: Hepatic Toxicity Following Treatment for Pediatric Graves’ Disease Meeting: October 28, 2008. Conference Proceeding: Hepatic Toxicity Following Treatment for Pediatric Graves’ Disease Meeting: October 28, 2008, http://bpca.nichd.nih.gov/outreach/index.cfm . 2009. (Accessed January 14, 2009, at http://bpca.nichd.nih.gov/outreach/index.cfm .)
3. Smith J, Brown RS: Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid. 2007, 17: 1103-1107.
4. Rivkees SA, Sklar C, Freemark M: Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metabol. 1998, 83: 3767-3776.
5. Weetman AP: Grave's disease 1835–2002. Horm Res. 2003, 59 (Suppl 1): 114-118.